CLINICAL TRIAL

Neural Stem Cells for Stroke

Recruiting · 18+ · All Sexes · Stanford, CA

This study is evaluating whether a drug may help improve outcomes for individuals with traumatic brain injury.

See full description

About the trial for Stroke

Eligible Conditions
Stroke · Ischemic Stroke · Ischemia

Treatment Groups

This trial involves 2 different treatments. Neural Stem Cells is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Neural Stem Cells
BIOLOGICAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The person is willing to take tacrolimus (Prograf) two days before the transplant and for two months after the transplant. show original
This text is about the age group of 18 to 75 years show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 0-12 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 0-12 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Neural Stem Cells will improve 2 primary outcomes in patients with Stroke. Measurement will happen over the course of 0-12 months.

Fugl Meyer (FM) motor score
0-12 MONTHS
Change in neurologic functional outcome to evaluate efficacy post-injection as defined by change in Fugl Meyer motor score in comparison to baseline
Incidence of Treatment-Emergent Adverse Events
0-12 MONTHS
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get stroke a year in the United States?

About 2.7 million people have a stroke annually in the United States. This makes it the second most common cause of disability after heart disease.

Anonymous Patient Answer

What is the average age someone gets stroke?

Results from a recent clinical trial has shown that the median age for having a stroke was 64 years old. This means that 6.4 per cent of the population over the age of 18 is likely to have a stroke at any one time.

Anonymous Patient Answer

What causes stroke?

Stroke was not directly related to any one single cause. Factors such as age, sex, vascular risk profiles, co-morbidities and social environment seem to be more important in determining the occurrence of a stroke and its outcome.

Anonymous Patient Answer

What are common treatments for stroke?

Many treatments are used worldwide, but the quality of evidence is generally poor. Although there are no effective treatments for stroke itself, there are many possible treatments for complications such as depression, weakness of limbs, and/or dysphagia that can occur after stroke. These treatments are used to provide patients with their best possible outcomes. The quality of evidence for treatments to improve symptoms is variable but there is an increasing body of evidence that proves that it is possible to optimize outcomes with these treatments. There are a large number of treatments to control symptoms and maximize recovery and return to everyday activities after a stroke. Some treatments may reduce the severity of symptoms and minimize damage to certain areas of the brain, but most are used only to help people control their lives.

Anonymous Patient Answer

What are the signs of stroke?

Stroke patients may experience disorientation, aphasia, and anhedonia, although these are not always present. Nausea and lethargy are typically prominent on admission. In terms of prognosis, patients with symptomatic arterial occlusion have a mortality risk three-to-four times higher during hospital admission.

Anonymous Patient Answer

What is stroke?

More than one-third of stroke patients have some neurological deficits or signs of stroke at admission. Stroke can be divided into 3 subgroups: acute ischemic stroke, hemorrhagic stroke, and intracerebral hemorrhage. Patients presenting with acute subacute symptoms of stroke should be considered for acute stroke work-up to determine subtype and risk factors. In patients with acute ischemic stroke a head CT scan will confirm and localize embolus and ischaemic lesion, and may help guide further management.

Anonymous Patient Answer

Can stroke be cured?

A significant proportion of patients admitted to a stroke unit will never return and need long-term health care in the community. There is no evidence that a single stroke unit will affect all patients with stroke.

Anonymous Patient Answer

What does neural stem cells usually treat?

There were two types of brain injuries. The first type was that of a large hemispheric infarction (stroke). The second was damage caused by traumatic brain trauma. The brain stem cells transplanted and administered the treatments with very low recovery percentage values, not significantly better than the control group. Therefore, NSCs do not make a significant effect on repairing brain stem damage, especially in the case of stroke rehabilitation in adults who have already achieved recovery and are not in a very critical condition.

Anonymous Patient Answer

What is the primary cause of stroke?

The analysis indicated several important relationships between risk factors, stroke syndromes, and brain lesion patterns. We propose new models to understand stroke etiology. It has also been suggested that a new approach for stroke therapy should be considered.

Anonymous Patient Answer

How serious can stroke be?

The occurrence of a major neurological event is common after stroke. It is imperative to accurately diagnose the type of stroke, determine the severity and to manage the stroke appropriately. Stroke is a global illness leading to prolonged functional disability, decreased stroke accounts for 2-3% of deaths and is a source of great morbidity, it is the most common reason for hospitalisation and can be avoided.

Anonymous Patient Answer

What are the latest developments in neural stem cells for therapeutic use?

Because of the relatively low toxicity of neural stem cells, they are a promising tool for therapy, and this technology for stem cells may facilitate the creation of new treatments for other diseases.

Anonymous Patient Answer

What is neural stem cells?

In a recent study, findings suggest that neural stem cells have multiple, important functions and these could contribute to some pathological conditions such as stroke, Alzheimer’s disease, or Parkinson’s disease.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Stroke by sharing your contact details with the study coordinator.